Jessica Smith
Acute Care · Elyria, OHNPI 1669923207
Payments from drug & device makers
Across 34 payments — averaging $20.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$118
- Sanofi$82
- AstraZeneca$78
- Johnson & Johnson$53
- Viatris Specialty LLC$53
- Lundbeck LLC$51
- plus $249 from 10 others
What the payments were for
- Food & beverage$683100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 6 | $118 |
| Sanofi | 3 | $82 |
| AstraZeneca | 4 | $78 |
| Johnson & Johnson | 2 | $53 |
| Viatris Specialty LLC | 3 | $53 |
| Lundbeck LLC | 3 | $51 |
| Harmony Biosciences LLC | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| United Therapeutics Corporation | 2 | $30 |
| Insmed, Inc. | 1 | $23 |
| GSK | 1 | $21 |
| Vanda Pharmaceuticals Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$683 in reported general payments places this provider in the 70th percentile of 1,101 acute care providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 13 | $17,841 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $1,765 |
| Guanfacine Hcl | 14 | $536 |
| Meropenem | 13 | $507 |
| Quetiapine Fumarate | 44 | $351 |
| Atomoxetine Hcl | 12 | $328 |
| Prednisone | 67 | $223 |
| Hydroxyzine Pamoate | 20 | $201 |
| Montelukast Sodium | 11 | $164 |
| Trazodone Hcl | 21 | $159 |
| Buspirone Hcl | 32 | $158 |
| Aripiprazole | 15 | $154 |
| Azithromycin | 24 | $131 |
| Amoxicillin | 44 | $130 |
| Lamotrigine | 15 | $122 |
Paid to pharmacies, not to this prescriber.
Other acute care in Elyria
- Andrea RobinsonCleveland$149K
- Brittney BrowneMonroe$142K
- Jamie McGuireMiamisburg$86K
- Ileah ReichertColumbus$73K
- Davida PraterBeavercreek$46K
- Dawn FrenchAlliance$40K
- Holly McKibbenColumbus$23K
- Jody HussBlue Ash$13K
- Julie LurieCincinnati$13K
- Susan BrooksMount Vernon$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.